Amicus Therapeutics, Inc.FOLDNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
461.72%
↑ 3010% above average
Average (39q)
-15.87%
Historical baseline
Range
High:461.72%
Low:-650.84%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 461.72% |
| Q2 2025 | -19.14% |
| Q1 2025 | -149.79% |
| Q4 2024 | -26.26% |
| Q3 2024 | 44.71% |
| Q2 2024 | 153.99% |
| Q1 2024 | -650.84% |
| Q4 2023 | 78.31% |
| Q3 2023 | 9.74% |
| Q2 2023 | 49.89% |
| Q1 2023 | 11.08% |
| Q4 2022 | -25.08% |
| Q3 2022 | 44.17% |
| Q2 2022 | 19.55% |
| Q1 2022 | -4.43% |
| Q4 2021 | -70.16% |
| Q3 2021 | -9.18% |
| Q2 2021 | 26.80% |
| Q1 2021 | 18.17% |
| Q4 2020 | -22.88% |
| Q3 2020 | -2.76% |
| Q2 2020 | 34.22% |
| Q1 2020 | 12.32% |
| Q4 2019 | -55.35% |
| Q3 2019 | 25.02% |
| Q2 2019 | 5.97% |
| Q1 2019 | -16.98% |
| Q4 2018 | 55.51% |
| Q3 2018 | -232.79% |
| Q2 2018 | 16.47% |
| Q1 2018 | 16.99% |
| Q4 2017 | 75.41% |
| Q3 2017 | -484.84% |
| Q2 2017 | 9.52% |
| Q1 2017 | -14.55% |
| Q4 2016 | -1.04% |
| Q3 2016 | 7.42% |
| Q2 2016 | -12.89% |
| Q1 2016 | -3.89% |
| Q4 2015 | -8.79% |